Purpose of review Despite eliciting an early antiviral T cell response, HIV-specific T cells are unable to prevent disease progression, partly because of their loss of effector functions, known as T cell exhaustion. Restoring this T cell functionality represents a critical step for regaining immunological control of HIV-1 replication, and may be fundamental for the development of a functional cure for HIV. In this context, the use of animal models is invaluable for evaluating the efficacy and mechanisms of novel therapeutics aimed at reinvigorating T cell functions.
INTRODUCTION
Chronic viral infections are characterized by the persistence of antigen, which often contributes to the progressive loss of T cell function known as T cell exhaustion [1, 2] . Virus-specific T cells gradually lose their ability to proliferate and produce multiple cytokines, and thus become unable to effectively inhibit viral replication and eliminate the pathogen from the host [1] . Initial studies from the murine model of lymphocytic choriomeningitis demonstrated that signaling through inhibitory receptors, such as programmed death-1 (PD-1), is a key mechanism in limiting the function of CD8 þ T cells [3] . Since this description, increased levels of inhibitory receptors on virus-specific T cells have been found in the context of a number of chronic viral infections, including HIV-1 infection of humans and simian immunodeficiency virus (SIV) infection of rhesus macaques, and these levels have been found to correlate with viral load and declining CD4 þ T cell count, two measures of disease severity [4] [5] [6] [7] [8] [9] [10] . Therefore, numerous strategies have been explored to reverse this T cell exhaustion and increase T cell functionality in the context of HIV infection. Studies using nonhuman primate and humanized mouse models have become increasingly relevant a Emory Vaccine Center and b for evaluating the therapeutic potential of these reversion strategies in controlling HIV/SIV replication. Moreover, as HIV-1 eradication becomes a key priority in contemporary HIV/AIDS research, these animal models will also be critical in testing preclinically the ability of novel immune-based interventions to promote a functional cure.
Here, we review the recent studies in animal models that investigated the impact of blocking PD-1 signaling, the best characterized coinhibitory receptor, in controlling viral replication and restoring T cell function during HIV and SIV infection. We then discuss work that investigates these coinhibitory blockades as therapeutic and possibly curative agents. Finally, we comment on recent in-vitro data that support the use of targeting multiple mechanisms of T cell exhaustion, through combination therapy, and the future of translating these therapies into animal models and clinical practice.
CELL EXHAUSTION IN ANIMAL MODELS OF HIV/SIV
Virus-specific CD8 þ T cells are critical for the control of virus replication. Because of the inability of HIVspecific CD8
þ T cells to control HIV infection, as evidenced by the chronic viremia present in the majority of HIV-infected individuals, HIV-specific CD8 þ T cells were the primary focus of initial studies investigating cell exhaustion during HIV infection.
Early studies in the rhesus macaque model of SIV infection confirmed that SIV infection elicits an early and vigorous SIV-specific CD8 þ T cell response; however, these CD8 þ T cells are unable to prevent disease progression, consistent with human HIV infection [11] [12] [13] [14] . Through the demonstration of loss of cytokine production [namely, interleukin 2(IL-2) and interferon g (IFN-g)], cytotoxic activity, and ability to proliferate, SIV-specific CD8 þ T cells were found to become 'exhausted' during the chronic phase of SIV infection, and thus validated the use of rhesus macaques in the study of HIV/SIV pathogenesis. Since then, the nonhuman primate model has been utilized to identify cellular and molecular mechanisms that regulate the function, and dysfunction, of T cells during SIV infection.
Studies on both humans and nonhuman primates have demonstrated that signaling through coinhibitory receptors is one of the main mechanisms contributing to the induction of CD8 þ T cell exhaustion during HIV/SIV infection. PD-1, one of the prototypic inhibitory receptors, is upregulated following T cell receptor activation and signals a negative feedback mechanism to inhibit further T cell activation and proliferation [3, 15] . HIV-specific CD8 þ T cells have increased levels of PD-1 on their surface, which correlate with impaired CD8 þ T cell function and measures of disease progression [4, 7, 9] . Similarly, PD-1 expression is heightened on SIV-specific CD8 þ T cells [8, 10] . PD-1-expressing CD8 þ T cells, in these rhesus macaque studies, were found to have an impaired ability to proliferate and were increasingly prone to apoptosis. However, the ability of PD-1 to be induced simply upon T cell activation [16, 17] , as well as its expression on T cells from healthy individuals [18] , has recently caused a renewed interest in the use of PD-1 expression as a marker for T cell exhaustion.
In an effort to delineate the role of PD-1 expression during SIV/HIV infection, Hong et al. [19 & ] longitudinally examined the coexpression of PD-1 and Ki-67, a marker of T cell proliferation, on rhesus macaque T cells during SIV infection. Consistent with previous studies, SIV-specific CD8 þ T cells were found to have reduced proliferative capacity after chronic SIV infection, as determined by the absence of Ki-67 expression, which correlated with PD-1 expression levels [19 & ]. Yet, increased PD-1 expression was not exclusive to SIV-specific cells. In fact, the frequency of nonproliferating CD8 The use of coinhibitory receptor blockades, in combination with fully suppressive ART as a strategy for HIV-1 functional cure, is supported by recent studies in SIV-infected rhesus macaques, in which animals undergoing such a treatment experienced delayed viral rebound upon ART interruption.
Combination therapies, in which multiple mechanisms involved in T cell exhaustion are targeted, likely represent the next generation of strategies aimed at fully restoring T cell functionality and viral control and will likely require the future use of testing in animal models of HIV/SIV infection.
involves the gradual loss of multiple functions -not simply proliferation; therefore, the implications of this study are limited by a lack of coinciding data examining additional T cell dysfunctions as a result of SIV infection.
Although the mechanisms regulating the exhaustion of CD8 þ T cells have been well investigated, less work has been done to understand the regulation of CD4 þ T cell dysfunction during SIV/ HIV infection. Similar to CD8 þ T cells, HIV-specific CD4 þ T cells largely lose their chief functionsnamely, proliferation and cytokine secretion -early in the course of infection [20, 21] . This functional impairment also is associated with the increased expression of coinhibitory receptors on CD4
þ T cells [6, 22] . Recent work has demonstrated that concurrent expression of multiple coinhibitory factors [PD-1, cytotoxic T-lymphocyte antigen 4 (CTLA-4), and T cell immunoglobulin and mucin protein 3 (TIM-3)] on CD4 þ T cells is more strongly associated with lack of virus control than individual expression alone [23] . Similarly, CD4
þ T cells express elevated levels of PD-1 during SIV infection of rhesus macaques, which has been linked to the functional impairment of CD4 þ T cells because of their increased proliferative capacity as a result of invitro PD-1 blockade [10] . The close phenotypic and functional attributes of T cells during HIV and SIV infection have made the SIV/rhesus macaque model the leading animal model in evaluating therapies aimed at restoring T cell function, controlling virus replication, and ultimately slowing SIV disease progression.
PROGRAMMED DEATH-1 BLOCKADE DURING THE NATURAL HISTORY OF HIV/SIV INFECTION
The relationship between PD-1 overexpression and T cell exhaustion during HIV/SIV infection has made the use of in-vivo PD-1 blockade a promising therapeutic option to facilitate T cell functional restoration ( Table 1 ). The efficacy of PD-1 blockade was initially demonstrated in lymphocytic choriomeningitis-infected mice, in which blocking the PD-1 receptor reinvigorated effector CD8 þ T cells to eventually clear the chronic infection [3] . Early in-vitro studies extended the ability of PD-1 blockade to rescue the functions of both HIV-specific and SIV-specific CD8 þ and CD4 þ T cells, thus providing rationale for the first in-vivo trials of PD-1 blockade in the rhesus macaque model of SIV infection [9, 10] . Blockade of the PD-1 pathway in vivo resulted in increased SIV-specific T cell proliferation and cytokine production, SIV-specific B-cell responses, and remarkably prolonged survival of SIV-infected rhesus macaques [27] . The therapeutic benefit of PD-1 blockade was further demonstrated in a follow-up study, showing that PD-1 blockade in SIV-infected rhesus macaques reduced immune activation by dampening proinflammatory signals and partially improving mucosal integrity [28] . These studies have generated increased interest in determining the optimal dosing and staging of PD-1 blockade to best restore antiviral immunity, but also in evaluating its efficacy in inhibiting HIV-1 replication.
One early limitation to testing PD-1 blockade in SIV-infected rhesus macaques was the lack of an available recombinant macaque PD-1 antibody. In fact, the partially humanized PD-1 blocking antibody rapidly disappeared from the blood of the treated rhesus macaques as a result of xenogeneic antibody responses [27] . To overcome this limitation, Amancha et al. [26 && ] recently developed a fully primatized rPD-1-Fc fusion protein that is nonimmunogenic and able to block PD-1 ligation similar to previous blocking agents. Administration of this PD-1 blockade resulted in enhanced proliferation of SIV-specific CD4 þ T cells, as well as an increased frequency of polyfunctional SIV-specific CD8 þ T cells. However, this restoration of T cell function was insufficient to affect virus levels in the PD-1-blockade treated rhesus macaques, similar to a separate study of PD-1 blockade on SIV-infected rhesus macaques [29] . It is unclear whether this result was due to higher overall viral load set points in this cohort of SIV-infected rhesus macaques, compared with those tested by Velu et al. [27] , or if the treatment regimen was not optimal for the full restoration of antiviral T cell functionality.
Despite the immunologic and virologic parallels between HIV infection in humans and SIV infection in rhesus macaques, the effects of PD-1 blockade on SIV replication cannot always be assumed to mimic its effects on HIV-1 replication. Studying HIV-1 infection in vivo has also relied on the use of humanized mouse models, given the limited species tropism of HIV [30] . Yet, early humanized mouse models were limited in their ability to mount adaptive immune responses [31] . The recent generation of improved humanized mouse models that exhibit many clinical manifestations of HIV-1 disease, in addition to generating HIV-specific T cell responses, has created a new model for evaluating novel therapies for HIV-1 directly in vivo [32] [33] [34] [35] [36] . Two recent studies utilized these new models to investigate the efficacy of PD-1 blockade on HIV-1 replication in vivo [24 However, the effect on viral load was exclusive to BLT mice whose CD8 þ T cells expressed high levels of PD-1. This observation could be a result of increased levels of HIV-specific CD8 þ T cells, which would support the ability of PD-1 blockade to restore antiviral functionality in these animals. However, neither study was able to directly investigate the frequencies of HIV-specific CD8 þ T cells or the mechanism of viral suppression in these animals [24 Altogether, these recent studies agree with the previous literature in animal models that supports the use of PD-1 blockade to help restore antiviral immunity in HIV-infected individuals. Extending the use of PD-1 blockade to the treatment of HIVinfected individuals, though, will require further studies in animal models to best determine the schedule, dosing, and specificity of PD-1 blockade for optimal restoration of T cell functionality and subsequent viral control. The safety of humanized PD-1-blocking mAbs has recently been demonstrated in the context of late-stage metastatic malignancies, thus paving the way for future clinical trials of PD-1 blockade during HIV infection [38] [39] [40] [41] .
Additionally, these studies demonstrate the capacity of these animal models to model HIV-1 infection, and therefore, validate their use in evaluating the efficacy of novel immunotherapeutics.
PROGRAMMED DEATH-1 BLOCKADE DURING SUPPRESSIVE ANTIRETROVIRAL THERAPY
Despite the success of antiretroviral therapy (ART) in suppressing virus replication and dramatically decreasing the mortality and morbidity associated with HIV infection, a therapy that is able to eradicate the virus is still unavailable [42, 43] . One of the major barriers to HIV eradication is the presence of a persistent reservoir of latently infected cells that are not eliminated by ART [44, 45] . Therefore, identifying novel strategies that are able to reduce the size of the latent HIV reservoir, in addition to restoring antiviral immune function to T cells, represents a major priority in contemporary AIDS research.
Because a functional cure can only be achieved through restored immune control of the virus (in Table 1 . Summary of the main findings from testing coinhibitory receptor blockades in the context of active HIV/SIV replication in animal models from the annual period of review the absence of ART), interventions that reinvigorate exhausted T cells have become a major focus of HIV-1 cure research. The success of PD-1 blockade in restoring T and B cell functionality in SIVinfected rhesus macaques, while having a moderate impact on viremia, has provided support to the idea of combining this intervention with ART to improve the function of exhausted antiviral T cells [27] . In essence, the rationale is that these reinvigorated HIV-specific CD8 þ (and CD4 Table 2) . Amancha et al. [26 && ] found that only when SIVinfected rhesus macaques were treated with both rPD-1-Fc and ART (PMPA/racivir) did animals show slower rebound in plasma viral loads as compared with ART-treated rhesus macaques alone. Although drawing similar conclusions to the overall restoration potential of PD-1 blockade during SIV infection, Vargas-Inchaustegui et al. [46 & ] found slightly different responses based on treatment strategy. This study targeted PD-1 by using B7-DC-Ig, a fusion protein that acts primarily on cells expressing high levels of PD-1 on their surface [46 & ,48] , and combined this blockade with ART in chronically SIV-infected rhesus macaques. After ART interruption, animals that had received PD-1 blockade only throughout ART had similar viral rebounds to those treated with ART alone; however, animals which continued to receive PD-1 blockade upon ART interruption experienced reduced rebound viremia [46 & ]. In both studies, therefore, it can be speculated that improved functional T cell activities contribute to the slower rate of viral rebound. Nevertheless, the results of these studies are of somewhat difficult interpretation because of the lack of full viral suppression by ART prior to its interruption, which may contribute to persistent antigen exposure and T cell exhaustion despite ART.
Main effects
A recent study by Mason et al. [47 && ] investigated the ability of PD-1 blockade to restore SIV-specific T cell function, and thus facilitate host control of viral replication, in the setting of full viral suppression in ART-treated, SIV-infected rhesus macaques. In this study, viral rebound was delayed in half of the PD-1-blockade-treated rhesus macaques, compared with untreated controls, following ART interruption. Remarkably, a quarter of the animals receiving PD-1 blockade continued to have undetectable viral loads for up to 4 weeks following ART interruption (Table 2) . These results support a mechanism in which PD-1 blockade is responsible for the restoration of SIV-specific T cell functionality, allowing for partial control of virus replication and reduction of infected cells. However, all animals treated with PD-1 blockade eventually experienced viral rebound [47 && ], as did the less suppressed animals discussed above [26 && ,46 & ], suggesting that better control of viral replication will be necessary before PD-1 blockade can be hypothesized as a curative strategy. Achieving this level of immune control will likely require the careful combination of therapies that can reduce latent viral reservoirs with those that can reinvigorate antiviral T cell responses.
COMBINATION THERAPY: THE NEW FRONTIER TO RESTORING T CELL FUNCTIONALITY
Targeting multiple mechanisms involved in T cell exhaustion is an attractive strategy to more broadly reinvigorate the antiviral immune response in the Table 2 . Summary of the main findings from testing coinhibitory receptor blockades in the context of viral suppression by antiretroviral therapy in nonhuman primate models from the annual period of review setting of HIV infection. Apart from PD-1, several other coinhibitory molecules have been shown to regulate T cell responses, and be expressed at elevated levels, during chronic viral infections [5, 15, 49] . Increased levels of TIM-3, lymphocyte-activation gene 3 (LAG-3), CD160, and 2B4 have been found on HIV-specific CD8 þ T cells during chronic infection; likewise, HIV-specific CD4 þ T cells have elevated levels of CTLA-4 and TIM-3 on their surface [5] [6] [7] [50] [51] [52] [53] [54] . Particularly in the context of CD8 þ T cell dysfunction, greater coexpression of multiple coinhibitory receptors has been associated with more advanced stages of T cell exhaustion [5, 55] . Additionally, inhibitory molecules are under the control of different signaling networks [56] [57] [58] . Therefore, given the success of other coinhibitory receptor blockades in enhancing T cell proliferation and function in vitro [5, 6, 55, 59] , future studies that test the efficacy of dual and triple coinhibitory molecule blockades in vivo will be critical to determine whether targeting multiple molecular networks can better rescue T cell function during HIV/SIV infection.
The induction of regulatory CD4 þ T cells [regulatory T cell (Treg)] has been proposed as an additional mechanism contributing to CD8 þ T cell dysfunction during HIV infection [60] . Increases in Tregs have been reported in both chronic HIV and SIV infections, potentially enhancing viral replication through the suppression of antiviral effector T cell functions [60] [61] [62] [63] [64] [65] . However, inhibiting Treg function using CTLA-4 blockade in SIV-infected rhesus macaques resulted in increased viral replication and was unable to restore virus-specific immune responses, but instead, resulted in increased T cell activation and more pronounced CD4 þ T cell loss in these animals [66] . This finding may be a result of CTLA-4 blockade acting not only on Tregs but also on activated CD4
þ T cells expressing CTLA-4. Yet, murine models of chronic retroviral infections have found that transient, selective ablation of Tregs is able to reactivate previously exhausted CD8 þ T cells [67] . Therefore, a recent study by Dietze et al. [68 & ] investigated whether combining transient Treg depletion with two coinhibitory blockades (against PD-L1 and TIM-3) could restore CD8 þ T cell function and reduce viral loads in a murine model of chronic retrovirus infection. These authors found that, although blocking inhibitory receptors had the more significant effect on restoring CD8 þ T cell function compared with Treg depletion, the combination of the two therapies increased the CD8 þ T cell response greater than any single treatment alone. Although this particular combination approach may be difficult to translate into the treatment of HIV-infected individuals, this study provides important proof-ofconcept that one can simultaneously target different mechanisms of cell exhaustion and synergize these approaches to better restore antiviral T cell responses.
Building on data demonstrating that blocking the interleukin-10 (IL-10) pathway can increase HIV-specific CD4 þ T cell function [69] [70] [71] , Porichis et al. [72 && ] evaluated the impact of combining PD-L1 blockade with IL-10Ra blockade on restoring HIV-specific T cell function in vitro. Dual blockade significantly increased IFN-g production by HIVspecific CD4 þ T cells, compared with either treatment alone, suggesting that the simultaneous targeting of these two pathways can synergistically restore T helper cell function. However, it is unclear whether IFN-g secretion will be advantageous in controlling HIV-1 viral replication. Furthermore, they found that the combined blockade could still increase cytokine production by HIV-specific CD4 þ T cells from ART-treated subjects, though to a lesser extent than in T cells isolated from viremic individuals [72 && ]. Therefore, future studies will be necessary to expand these data and determine if these combined blockades can aid in restoring T cell function, as well as in purging latent viral reservoirs, in vivo. Taken together, these early studies provide essential support for the next generation of therapeutic strategies that combine blockades which target multiple regulatory pathways, and thus more effectively combat T cell exhaustion in the setting of HIV-1 infection.
CONCLUSION
Restoring HIV-specific T cell functionality by reversing exhaustion represents a critical step in regaining immunological control of HIV-1 replication and could prove essential for the attainment of a functional cure. As the mechanisms regulating cell exhaustion during HIV infection become more clear, in particular with respect to the role of coinhibitory receptors such as PD-1, nonhuman primate and humanized mouse models will become increasingly important for evaluating the efficacy of novel therapeutic strategies targeting these mechanisms. The latest data discussed here suggest that coinhibitory receptor blockades, namely PD-1 blockade, can reinvigorate CD8 þ T cells and delay viral rebound in vivo, and that these effects may be amplified by targeting multiple pathways of inhibition. Determining the optimal combination of blockades, in addition to schedule and dosing, should be of high priority in future animal studies. This study is the first of its kind to demonstrate the use of humanized mouse models for investigating the efficacy of novel therapies for HIV-1 infection, and importantly illustrates the potential of PD-1 blockade to reduce HIV-1 replication in vivo. 25.
